ERBB2 and breast carcinoma: T-DM1 was also compared with the treatment of physician’s choice in the phase III TH3RESA study in HER2-positive advanced breast cancer patients heavily pretreated with a median of four previous regimens for advanced disease, including trastuzumab and lapatinib, a taxane in any setting and with progression on two or more HER2-directed regimens.